Rigel Pharmaceuticals (RIGL) CFO Dean Schorno Exercises Options

What Happened
Dean L. Schorno, Chief Financial Officer of Rigel Pharmaceuticals (RIGL), exercised multiple stock options on 2026-09-02 to acquire a total of 4,600 common shares for an aggregate cash cost of about $99,929 (694 @ $12.70 = $8,814; 620 @ $18.70 = $11,594; 2,000 @ $24.20 = $48,400; 1,286 @ $24.20 = $31,121). On 2026-09-01, 928 shares were disposed (code F) at $47.50 for $44,080 to satisfy exercise price or tax withholding obligations. The filing also shows corresponding derivative instrument disposals at $0, which reflect the conversion/exercise of those options into common stock.

Key Details

• Transaction dates and amounts:
  • 2026-09-01: 928 shares disposed (tax/exercise withholding) @ $47.50 = $44,080 (code F)
  • 2026-09-02: Option exercises acquiring 4,600 shares total for ~$99,929 (prices as listed above; code M)
  • Several derivative disposals reported at $0 accompany the exercises (reflecting conversion)
• Shares owned after transaction: Not specified in the provided excerpt of the Form 4.
• Notable footnotes:
  • F1: Includes 500 shares acquired under the issuer’s employee stock purchase plan.
  • F2: Share figures adjusted for the 1-for-10 reverse split effective June 27, 2024.
  • F3–F6: Describe monthly vesting schedules for the underlying options from various commencement dates.
• Filing timeliness: Report filed 2026-09-03 covering transactions on 2026-09-01 and 09-02; this appears to be within the SEC’s standard reporting window.

Context: These were option exercises (code M). The 928-share disposal (code F) is a common tax-withholding or exercise-price payment mechanism and does not necessarily indicate a market-sale decision. The zero-dollar derivative disposals represent the termination/conversion of option instruments when exercised. This filing is factual disclosure of the exercises and withholding; it does not state any insider intent.